Literature DB >> 19949039

Optic neuropathy in patients with glioblastoma receiving bevacizumab.

J H Sherman1, D G Aregawi, A Lai, H M Fathallah-Shaykh, P J Bierman, K Linsky, J M Larner, S A Newman, D Schiff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19949039      PMCID： PMC2796439          DOI： 10.1212/WNL.0b013e3181c3fd00

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Taming glioblastoma: targeting angiogenesis.

Authors:  Eric T Wong; Steven Brem
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

2.  Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.

Authors:  Albert Lai; Emese Filka; Bruce McGibbon; Phioanh Leia Nghiemphu; Carrie Graham; William H Yong; Paul Mischel; Linda M Liau; Marvin Bergsneider; Whitney Pope; Michael Selch; Tim Cloughesy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-20       Impact factor: 7.038

3.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

4.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

5.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

6.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  6 in total
  15 in total

1.  In search of a treatment for radiation-induced optic neuropathy.

Authors:  Maanasa Indaram; Ferhina S Ali; Marc H Levin
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity.

Authors:  HuyTram N Nguyen; Kevin B H Vo; Steven Howard; M Shahriar Salamat; Howard Rowely; H Ian Robins
Journal:  Neurooncol Pract       Date:  2018-02-02

Review 3.  Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.

Authors:  Gerardo Gutiérrez-Gutiérrez; María Sereno; Ambrosio Miralles; Enrique Casado-Sáenz; Eduardo Gutiérrez-Rivas
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

4.  Unexpected late radiation neurotoxicity following bevacizumab use: a case series.

Authors:  Paul J Kelly; Marc J Dinkin; Jan Drappatz; Kevin N O'Regan; Stephanie E Weiss
Journal:  J Neurooncol       Date:  2010-08-01       Impact factor: 4.130

Review 5.  Bevacizumab for radiation necrosis following treatment of high grade glioma: a systematic review of the literature.

Authors:  Daniel Lubelski; Kalil G Abdullah; Robert J Weil; Nicholas F Marko
Journal:  J Neurooncol       Date:  2013-09-05       Impact factor: 4.130

6.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Authors:  Albert Lai; Anh Tran; Phioanh L Nghiemphu; Whitney B Pope; Orestes E Solis; Michael Selch; Emese Filka; William H Yong; Paul S Mischel; Linda M Liau; Surasak Phuphanich; Keith Black; Scott Peak; Richard M Green; Cynthia E Spier; Tatjana Kolevska; Jonathan Polikoff; Louis Fehrenbacher; Robert Elashoff; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

Review 7.  Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

Authors:  Rimas V Lukas; Minesh P Mehta; Maciej S Lesniak
Journal:  Neurooncol Pract       Date:  2015-03-24

Review 8.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 9.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

10.  Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

Authors:  Katsuyuki Shirai; Michael R Siedow; Arnab Chakravarti
Journal:  J Oncol       Date:  2011-07-14       Impact factor: 4.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.